Develops a proprietary platform that decodes the extracellular matrix (ECM) to identify novel drug targets and biomarkers for fibrotic diseases and solid tumors. By targeting disease-specific changes in ECM protein bioactivity and deposition, it aims to improve clinical outcomes and accelerate the development of therapeutic candidates in partnership with pharmaceutical companies.
Funding
$60.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current drug discovery and development processes for fibrotic diseases and solid tumors face high failure rates due to the limitations of traditional in vitro and in vivo models. These models often fail to accurately replicate the complexity of human tissues and the critical role of the extracellular matrix (ECM), leading to ineffective therapeutic candidates. An incomplete understanding of disease-specific ECM changes further hinders the identification of relevant drug targets and biomarkers.
Solution
Engitix Therapeutics is developing a human ECM-based platform to improve target identification, drug discovery, and drug development for fibrotic diseases and solid tumors. The platform decodes the ECM by analyzing disease-associated changes in its composition, structure, and abundance. By integrating bioactive, human ECM into preclinical models, Engitix recreates the natural cell microenvironment, enabling the study of biological impacts and evaluation of therapeutic strategies. This approach facilitates the discovery of novel therapeutic targets and biomarkers and enhances the prediction of drug efficacy at an early stage.
Target Audience
Engitix's primary customers are pharmaceutical and biotech companies focused on developing therapies for fibrotic diseases and solid tumors.
Features
- Proprietary in vitro 3D tissue-specific and disease-specific screening platform
- Human ECM-based models that incorporate structural support, biophysical cues, and biochemical signals
- Identification of disease-associated changes in ECM composition
- Target discovery and validation using human ECM cell culture models
- Drug profiling in a natural cell microenvironment
- Partnerships with pharmaceutical companies to develop effective therapies